Company Overview of Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel and small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include Fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase III clinical trials for the treatment of rheumatoid arthritis; R343, an inhaled SYK inhibitor that is in Phase II clinical trials to treat asthma; R333, a topical dermatological janus kinase (JAK)/SYK inhibitor, which is in Phase II clinical trials for the treatment of discoid lupus erythematosus; and R348, a topical ophthalmic JAK/SYK inhibitor that is in Phase ...
1180 Veterans Boulevard
South San Francisco, CA 94080
Founded in 1996
Key Executives for Rigel Pharmaceuticals, Inc.
Total Annual Compensation: $671.6K
President and Chief Operating Officer
Total Annual Compensation: $533.1K
Total Annual Compensation: $540.6K
Chief Financial Officer
Total Annual Compensation: $426.4K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $503.7K
Compensation as of Fiscal Year 2012.
Rigel Pharmaceuticals, Inc. Key Developments
AstraZeneca AB Scraps Collaboration Pact with Rigel Pharmaceuticals, Inc. After Arthritis Drug Stalls in Phase III Tests
Dec 6 13
Rigel Pharmaceuticals, Inc. announced that AstraZeneca AB (AZN) terminated a licensing and collaboration agreement between the companies on RIGL's prospective arthritis drug. Under terms of the February 2010 agreement AZN was responsible for conducting and funding all future development, regulatory filings, manufacturing and global commercialization of products containing RIGL's fostamatinib drug candidate, an oral spleen tyrosine kinase inhibitor. The December 4, 2013, decision follows top-line results released in June from a pair of Phase III trials of fostamatinib after the drug failed to demonstrate a statistically significant difference in modified Total Sharp Score compared with a placebo after 24 weeks. As a result of the termination of the agreement, all rights to fostamatinib revert to RIGL.
Rigel Pharmaceuticals, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013
Nov 5 13
Rigel Pharmaceuticals, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2013. For the third quarter of 2013, Rigel reported a net loss of $23.8 million, or $0.27 per share, compared to a net loss of $25.5 million, or $0.36 per share, in the same period of 2012. Loss from operations was $23,930,000 against $25,569,000 a year ago.
For the nine months ended September 30, 2013, Rigel reported a net loss of $72.2 million, or $0.83 per basic and diluted share, compared to a net loss of $73.4 million, or $1.03 per basic and diluted share, for the same period of 2012. Loss from operations was $72,525,000 against $73,761,000 a year ago. Contract revenues were $1,400,000 against $2,250,000 a year ago.
Rigel Provides Update on Pipeline Products
Oct 24 13
Rigel Pharmaceuticals, Inc. announced updates on two of the company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor. R333 Update:- The company announced that R333, which was being evaluated as a potential therapeutic for active skin lesions in patients with discoid lupus erythematosus (DLE), did not meet the primary endpoint in a recently completed Phase 2 clinical study. The primary endpoint was the proportion of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4. R333 was shown to be relatively safe and well tolerated. In light of these overall findings, Rigel has decided not to pursue this indication further with R333. Fostamatinib Update:- the representatives met with the FDA for an end-of-Phase 2 meeting for fostamatinib, an oral SYK inhibitor in development for patients with immune thrombocytopenic purpura (ITP). Rigel expects to initiate two pivotal Phase 3 studies in the first half of 2014. Each of these trials are expected to enroll approximately 75 patients who would be treated for six months and have the option to enroll in an extension study. These trials will be randomized, placebo-controlled and will enroll verified ITP patients with platelet counts below 30,000 platelets per microliter of blood. The goal of the trials will be to achieve a durable platelet count increase to over 50,000 platelets per microliter of blood. Rigel expects top line data from these studies in 2015.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|